ATLANTIC CITY, N.J. - (Mealey's) A New Jersey state court jury on April 18 returned a defense verdict for Merck, Sharpe & Dohme in a Fosamax jaw injury trial, the company said in a press release ( Jo Ann Sessner v. Merck, Sharpe & Dohme, Inc... Read More
WASHINGTON, D.C. — (Mealey’s) The U.S. Supreme Court on Oct. 7 refused to hear arguments by Novartis Pharmaceuticals Corp. that federal drug regulations and high court precedent preempt the awarding of state law punitive damages in an Aredia... Read More
NEW BRUNSWICK, N.J. - (Mealey's) A New Jersey state court jury on May 15 returned a defense verdict for Novartis Pharmaceuticals Corp. in a Zometa jaw injury case, a source told Mealey Publications ( Beverly Meng v. Novartis Pharmaceuticals Corp.... Read More
NEW YORK - (Mealey's) A jury returned an $8 million compensatory damages verdict against Merck & Co. Inc. on June 25 in the U.S. District Court for the Southern District of New York in the retrial of the first Fosamax multidistrict litigation... Read More
NEW YORK — (Mealey’s) The second federal Fosamax bellwether trial ended in a defense verdict May 6 when a jury in the U.S. District Court for the Southern District of New York unanimously found that the plaintiff did not suffer from osteonecrosis... Read More
NEW YORK -- (Mealey's) The New York federal judge overseeing the Fosamax multidistrict litigation on Oct. 4 sua sponte found that an $8 million verdict in a bellwether trial is excessive and ordered a remittitur of the verdict to $1.5 million unless... Read More
NEW BRUNSWICK, N.J. -- A New Jersey state court jury on Oct. 6 found that Novartis Pharmaceuticals Corp. did not fail to provide adequate warning to a cancer patient's doctor that its bone-saving drugs Aredia and Zometa had a risk of osteonecrosis... Read More
NEW YORK - A New York federal jury hearing the fourth Fosamax bellwether trial on Oct. 3 found that Merck's osteoporosis drug was not defectively designed and did not cause a plaintiff to develop osteonecrosis of the jaw (ONJ) ( In Re: Fosamax Products... Read More
ORLANDO, Fla. — (Mealey’s) A Florida federal jury on Sept. 20 found that Novartis Pharmaceuticals Corp. failed to warn a cancer patient about the risk of osteonecrosis of the jaw (ONJ) and awarded her $1.3 million in medical expenses and non... Read More
ATLANTIC CITY, N.J. -- The first state court trial alleging jaw injuries from Fosamax yielded a win for the defense on Feb. 14 in the Atlantic County, N.J., Superior Court ( Alison Rosenberg v. Merck, Sharpe & Dohme Corp. , No. ATL-L-3644-08, N.J... Read More
RICHMOND, Va. - (Mealey's) Virginia does not recognize either equitable or statutory tolling for class actions brought by different plaintiffs in another jurisdiction, the Virginia Supreme Court ruled March 2 in an appeal by four Fosamax jaw injury... Read More
CENTRAL ISLIP, N.Y. - (Mealey's) A New York federal jury on Nov. 2 found Novartis Pharmaceuticals Corp. liable for a woman's osteonecrosis of the jaw (ONJ) and awarded her $10.45 million, according to the parties ( Barbara Davids v. Novartis Pharmaceuticals... Read More
NEW YORK - (Mealey's) A New York federal jury on Feb. 5 ordered Novartis Pharmaceuticals Corp. to pay $285,000 to a plaintiff for allegedly failing to warn her or her doctor that Fosamax carries a risk of osteonecrosis of the jaw (ONJ) ( In Re: Fosamax... Read More
NEW YORK - (Mealey's) The second bellwether plaintiff in the Fosamax multidistrict litigation failed to produce evidence that the osteoporosis drug caused her osteonecrosis of the jaw (ONJ), a panel of the Second Circuit U.S. Court of Appeals ruled... Read More
BROOKLYN, N.Y. (Mealey's) A New York federal jury in the first federal Zometa trial found May 25 that the plaintiff did not prove by a preponderance of evidence that the Novartis Pharmaceuticals Corp. drug caused a decedent's osteonecrosis of... Read More